Journal of Cancer Research and Clinical Oncology最新文献

{"title":"Deep learning and radiomics for gastric cancer serosal invasion: automated segmentation and multi-machine learning from two centers.","authors":"Hui Shang, Tao Feng, Dong Han, Fengying Liang, Bin Zhao, Lihang Xu, Zhendong Cao","doi":"10.1007/s00432-025-06117-w","DOIUrl":"10.1007/s00432-025-06117-w","url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study is to develop an automated method for segmenting spleen computed tomography (CT) images using a deep learning model. This approach is intended to address the limitations of manual segmentation, which is known to be susceptible to inter-observer variability. Subsequently, a prediction model of gastric cancer (GC) serosal invasion was constructed in conjunction with radiomics and deep learning features, and a nomogram was generated to explore the clinical guiding significance.</p><p><strong>Methods: </strong>This study enrolled 311 patients from two centers with pathologically confirmed of GC. we employed a deep learning model, U-Mamba, to obtain fully automatic segmentation of the spleen CT images. Subsequently, radiomics features and deep learning features were extracted from the entire spleen CT images, and significant features were identified through dimensionality reduction. The clinical features, radiomic features, and deep learning features were organized and integrated, and five machine learning methods were employed to develop 15 predictive models. Ultimately, the model exhibiting superior performance was presented in the form of a nomogram.</p><p><strong>Results: </strong>A total of 18 radiomics features, 30 deep learning features, and 1 clinical features were deemed valuable. The DLRA model demonstrated superior discriminative capacity relative to other models. A nomogram was constructed based on the logistic clinical model to facilitate the usage and verification of the clinical model.</p><p><strong>Conclusion: </strong>Radiomics and deep learning features derived from automated spleen segmentation to construct a nomogram demonstrate efficacy in predicting serosal invasion in GC. Concurrently, fully automated segmentation provides a novel and reproducible approach for radiomics research.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"60"},"PeriodicalIF":2.7,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11790706/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex-specific differences in recurrence and progression following cytostatic intravesical chemotherapy for non-muscle invasive urothelial bladder cancer (NMIBC).","authors":"Laila Schneidewind, Bernhard Kiss, Thomas Neumann, Jennifer Kranz, Friedemann Zengerling, Sebastian Graf, Annabel Graser, Annemarie Uhlig","doi":"10.1007/s00432-025-06108-x","DOIUrl":"10.1007/s00432-025-06108-x","url":null,"abstract":"<p><strong>Purpose: </strong>To systematically analyze gender-specific differences in recurrence-free survival (RFS), progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS) as well as adverse events and quality of Life (QoL) as secondary aims in NMIBC patients undergoing cytostatic intravesical chemotherapy.</p><p><strong>Methods: </strong>A systematic review and meta-analysis were conducted on studies published between 1976 and 2024, following PRISMA guidelines. MEDLINE, Embase and Cochrane Library were used as literature sources. No restrictions were made concerning language, study region or publication type. Data from 12 studies encompassing 1,527 patients were analyzed. Outcomes were assessed using random-effects models, with gender as a primary variable of interest. A risk of bias assessment was done using the ROBINS-I tool or RoB2 as appropriate.</p><p><strong>Results: </strong>The pooled analysis demonstrated no statistically significant gender-specific differences in RFS (HR = 1.0625, 95% CI 0.8094-1.0526) or PFS (HR = 1.0861, 95% CI 0.7038-1.6760). Data on CSS and OS were insufficient for meaningful conclusions. Two included studies analyzed in univariate or multivariate regression gender as risk factor for recurrence or progression, but gender was not a significant risk factor. Adverse events and QoL outcomes were notably underreported, with no gender-specific data available.</p><p><strong>Conclusions: </strong>While this study found no significant gender-based differences in NMIBC outcomes following intravesical chemotherapy, the findings are limited by the small number of studies, underrepresentation of women, and inconsistent reporting of critical outcomes. Future research should prioritize gender-focused analyses and explore the molecular and genetic basis of potential differences to inform precision medicine and equitable care.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"59"},"PeriodicalIF":2.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11787168/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143073719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomarker microRNA-371a-3p - expression in malignancies other than germ-cell tumours.","authors":"Gazanfer Belge, Markus Klemke, Bendix Hansen, Cansu Dumlupinar, Aylin Igde, Dirk Arnold, Hans Salwender, Christian Wülfing, Armin Soave, Klaus-Peter Dieckmann","doi":"10.1007/s00432-025-06101-4","DOIUrl":"10.1007/s00432-025-06101-4","url":null,"abstract":"<p><strong>Purpose: </strong>microRNA-371a-3p (M371) is considered a highly sensitive and specific serum biomarker of testicular germ cell tumours (GCTs). However, little is known about the expression of M371 in nontesticular malignancies (NTMs), so far. As knowledge about the expression of the marker in other malignancies is a prerequisite for the clinical application of the test we aimed to explore the M371 expression in other cancers.</p><p><strong>Methods: </strong>M371 serum levels were measured in 137 patients with NTM of 12 different neoplastic entities using the IVDR-certified M371-Test for quantitative real-time PCR. Median M371 serum levels and percentages of M371 level elevations were calculated for the entire NTM group and for entity-specific subgroups. The results were compared with GCT patients (n = 20) and with tumour-free male controls (n = 20) using descriptive statistical methods.</p><p><strong>Results: </strong>Eight patients with NTMs had M371 serum level elevations, corresponding to a false-positive rate (FPR) of 5.84% (95% confidence intervals (CIs) 2.55-11.18%). Expression rates in GCTs and controls were 100% and zero, respectively. Thus, the specificity of the M371-Test for GCT is 94.90% (95% CI 90.21-97.77%) when all NTMs and tumour-free controls are considered. Remarkably, three out of 5 patients with multiple myeloma had elevated M371 levels.</p><p><strong>Conclusion: </strong>The false-positive rate of the M371-Test in other malignancies than GCT is very low, and almost identical with that in healthy males, corresponding to a high specificity of 94.9% for detection of GCT. The surprising finding of M371 elevations in patients with multiple myeloma needs further investigation.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"58"},"PeriodicalIF":2.7,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11785664/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143065838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Individual management and prognostic assessment for long-term outcomes using a novel classification system of craniopharyngiomas: a retrospective study of single institution.","authors":"Sen Zhang, Bo Xie, Yi He, Xingshu Zhang, Gu Gong, Mingrui Li, Yinhua Chen, Guodong Tang, Chi Zhang, Chaoying Qin, Qing Liu","doi":"10.1007/s00432-025-06104-1","DOIUrl":"10.1007/s00432-025-06104-1","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to propose a classification system to more accurately understand the features and nature of different CPs, to investigate the correlation between different topographies of CPs and their surgical outcomes.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 91 surgically resected CPs. They were categorized into six types based on their location and origin. Simultaneously, the patients were divided into four categories based on the degree of pituitary stalk(PS) preservation postoperatively. Statistical analysis was performed to compare the variables among the different tumor type groups.</p><p><strong>Results: </strong>A total of 91 patients were included. The follow-up data for 59 cases were complete. Tumor volume varied significantly, with the suprasellar-third ventricle type II and ectopic type exhibiting larger volumes (P < 0.05). The choice of surgical approach differed significantly. The recurrence rates were significantly lower for the intrasellar-suprasellar type, suprasellar-third ventricle type II, and third ventricle type (P < 0.05). Patients with intra-stalk tumor growing pattern have a lower degree of PS preservation than those with peri-stalk pattern (P < 0.05). Patients' BMI after surgery was generally higher than before, and the incidence of pituitary dysfunction increased significantly. The proportion of long-term endocrine dysfunction was significantly higher in patients with complete disconnection of PS compared to those with preservation of the PS(P < 0.05).</p><p><strong>Conclusions: </strong>This system holds significant importance in foretelling the rates of recurrence, alterations in postoperative body weight, long-term endocrine status, and potential complications. Furthermore, this study identified preoperative pituitary function status and specific surgical approaches as potential protective factors.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"57"},"PeriodicalIF":2.7,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11785668/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143065842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the diagnostic potential of SATB2 and β-catenin as biomarkers and therapeutic targets in pancreatic ductal adenocarcinoma.","authors":"Noha Said Helal, Sara Maher, Safia Samir, Hesham A Elmeligy, Mohammed A Aboul-Ezz, Tarek Aboushousha, Mona Moussa","doi":"10.1007/s00432-024-06055-z","DOIUrl":"10.1007/s00432-024-06055-z","url":null,"abstract":"<p><strong>Introduction: </strong>Pancreatic ductal adenocarcinoma (PDAC) is associated with poor prognosis. The roles of the transcription factor special AT-rich binding protein-2 (SATB2) and β-catenin in PDAC have been a subject of controversy. We aimed to assess the diagnostic and prognostic impact of SATB2 and β-catenin in PDAC.</p><p><strong>Methods: </strong>We analyzed 44 paraffin-embedded tissue blocks along with corresponding blood and pancreatic tissues. We evaluated SATB2 expression using immunohistochemistry (IHC) and enzyme-linked immunosorbent assay (ELISA). β-catenin was assessed using IHC and real-time polymerase chain reaction (qPCR).</p><p><strong>Results: </strong>High SATB2 expression and low β-catenin expression were associated with a poor prognosis in PDAC, including advanced pathological tumor stage (pT-stage), pathological lymph node stage (pN-stage), and TNM stage. We found a positive correlation between SATB2 expression assessed by IHC and the concentration of SATB2 in both serum and tissue samples measured by ELISA. We observed a positive correlation between β-catenin expression assessed by IHC and β-catenin levels measured by qPCR.</p><p><strong>Conclusions: </strong>SATB2 and β-catenin could provide valuable insights into the development of pancreatic cancer, and targeting them may be beneficial for the prevention and treatment of PDAC. The levels of SATB2 in serum show promise for the diagnosis and tumor invasion of pancreatic cancer.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"56"},"PeriodicalIF":2.7,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11779791/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143059239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SHP2 promotes the epithelial-mesenchymal transition in triple negative breast cancer cells by regulating β-catenin.","authors":"Shihan Qian, Jingjing Zhu, Qing Han, Huang Cheng, Huaibin Zhou","doi":"10.1007/s00432-025-06097-x","DOIUrl":"10.1007/s00432-025-06097-x","url":null,"abstract":"<p><strong>Purpose: </strong>Growing evidence suggests that the tyrosine phosphatase SHP2 is pivotal for tumor progression. Triple-negative breast cancer (TNBC) is the most lethal subtype of breast cancer, characterized by its high recurrence rate, aggressive metastasis, and resistance to chemotherapy. Understanding the mechanisms of tumorigenesis and the underlying molecular pathways in TNBC could aid in identifying new therapeutic targets.</p><p><strong>Methods: </strong>In this study, we conducted bioinformatics analysis of the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases to examine PTPN11 (encoding SHP2) expression levels and perform survival analysis in TNBC. Additionally, we analyzed SHP2 levels in four TNBC cell lines and a normal breast epithelial cell line using Western blot. Furthermore, we knocked down SHP2 expression via RNA interference in three TNBC cell lines. To assess the impact of SHP2 on invasion and migration, we conducted transwell assays and wound healing experiments. An in vivo experiment utilizing a mouse xenograft model was also performed to evaluate tumor metastasis. Moreover, we detected the expression levels of epithelial-mesenchymal transition (EMT) biomarkers and investigated the mechanism between SHP2 and β-catenin using Western blot and immunofluorescence experiments.</p><p><strong>Results: </strong>We found that high SHP2 expression was associated with a poor prognosis in patients with TNBC. The migratory and invasive abilities of TNBC cells in vitro, as well as the metastatic potential of TNBC in mouse xenograft models, were reduced after SHP2 depletion. Downregulation of SHP2 also decreased the expression of mesenchymal markers but induced upregulation of the epithelial marker E-cadherin. Additionally, SHP2 promoted β-catenin stability by inhibiting its degradation via the proteasome. Furthermore, c-Myc expression and GSK3β and AKT phosphorylation, which are involved in β-catenin signaling, were decreased in SHP2-depleted TNBC cells.</p><p><strong>Conclusion: </strong>Our study demonstrates that SHP2 is involved in migration, invasion, and EMT in TNBC cells by modulating β-catenin. Manipulating SHP2 expression or its target protein β-catenin may offer a novel approach to TNBC therapy.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"55"},"PeriodicalIF":2.7,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11779776/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The global, regional, and national burden of oral cancer, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.","authors":"Junmeng Wu, He Chen, Yingjun Liu, Ruotong Yang, Na An","doi":"10.1007/s00432-025-06098-w","DOIUrl":"10.1007/s00432-025-06098-w","url":null,"abstract":"<p><strong>Purpose: </strong>This epidemiological study leverages data from the Global Burden of Disease (GBD) database spanning from 1990 to 2021 to analyze the global burden of oral cancer. The research aims to provide a comprehensive assessment of the age-standardized incidence rate (ASIR), age-standardized mortality rate (ASDR), and disability-adjusted life years (DALYs) for oral cancer, examining trends over three decades.</p><p><strong>Methods: </strong>The study used age standardized rate (ASRs) as an indicator of oral cancer epidemiological data. Trend analysis uses estimated annual percentage change (EAPC) to track changes in oral cancer indicators.</p><p><strong>Results: </strong>The study identifies a global increase in oral cancer incidence, mortality, and DALYs. From 1990 to 2021, the global incidence rate increased significantly from 3.26 (95% UI 3.14-3.41) to 5.34 (95% UI 4.94-5.70), the global mortality rate rose from 1.83 (95% UI 1.73-1.92) to 2.64 (95% UI 2.42-2.84), and the global estimate of DALYs increased from 55.05 (95% UI 52.38-57.97) to 74.44 (95% UI 67.50-80.44). High-risk regions include Palau and certain areas in Asia. Middle SDI regions show the most significant growth, while economically underdeveloped areas like parts of Africa show less significant trends.</p><p><strong>Conclusion: </strong>The research underscores the need for heightened awareness, surveillance, and prevention efforts, especially in regions with high oral cancer incidence. Policymakers are urged to implement screening programs and public health education to combat the disease.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"53"},"PeriodicalIF":2.7,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11775039/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospective study from Korea and Japan.","authors":"Jaekyung Cheon, Shigeo Shimose, Hyung-Don Kim, Takashi Niizeki, Min-Hee Ryu, Tomotake Shirono, Baek-Yeol Ryoo, Hideki Iwamoto, Changhoon Yoo","doi":"10.1007/s00432-025-06085-1","DOIUrl":"10.1007/s00432-025-06085-1","url":null,"abstract":"<p><strong>Purpose: </strong>Atezolizumab-bevacizumab (AB) is the established first-line systemic therapy for patients with unresectable hepatocellular carcinoma (uHCC). However, the optimal second-line treatment for patients unresponsive to AB remains undefined.</p><p><strong>Patients and methods: </strong>This multicenter, retrospective study included patients with uHCC who underwent second-line treatment with lenvatinib (LEN) or sorafenib (SOR) after AB failure at two academic centers between June 2018 and November 2023. Treatment response was assessed using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and modified RECIST. Propensity score matching (PSM) was employed to mitigate confounding bias.</p><p><strong>Results: </strong>A total of 123 were included in the final analysis, 56 patients received LEN, and 67 received SOR. Before PSM, LEN was associated with significantly improved progression-free survival (PFS) compared with SOR (median 4.9 vs. 3.3 months, p < 0.001); however, no significant difference in overall survival (OS) was observed (median 13.2 vs. 11.5 months, p = 0.651). After PSM, in a cohort of 50 patients (25 per each group), LEN maintained its PFS advantage over SOR (median 4.8 vs. 3.3 months, p = 0.046), while the median OS was longer with LEN but not statistically different (median 11.4 vs. 7.9 months, p = 0.197). Response rates were 40% for LEN and 12% for SOR (p = 0.021) based on modified RECIST, and 12% and 8% (p = 0.728) based on RECIST v1.1, respectively.</p><p><strong>Conclusion: </strong>In this real-world study, LEN demonstrated superior PFS and comparable OS to SOR as second-line treatment for uHCC after progression on AB.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"52"},"PeriodicalIF":2.7,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11775054/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of mortality risk scores after esophagectomy.","authors":"Sabine Schiefer, Nerma Crnovrsanin, Ingmar F Rompen, Nicolas Jorek, Mohammed Al-Saeedi, Thomas Schmidt, Henrik Nienhüser, Leila Sisic","doi":"10.1007/s00432-024-06074-w","DOIUrl":"10.1007/s00432-024-06074-w","url":null,"abstract":"<p><strong>Purpose: </strong>Oncological esophagectomy is the mainstay in esophageal cancer treatment, but perioperative mortality remains a significant concern. Various scoring systems exist to identify patients at high risk for postoperative complications and death. In the following, we aim to evaluate and compare these different scoring systems.</p><p><strong>Methods: </strong>We analyzed data from 714 patients who underwent esophagectomy between 2002 and 2021. Each patient's risk was calculated using three models: the International Esodata Study Group (IESG) 90-day mortality risk prediction, the Steyerberg 30-day mortality score, and the Fuchs et al. preoperative in-hospital mortality score (Fuchs score). The diagnostic performance of these models was assessed using the area under the receiver operating characteristic (ROC) curves.</p><p><strong>Results: </strong>Of the 714 patients, the majority (87.67%) underwent abdomino-thoracic esophagectomy with intrathoracic anastomosis. The IESG score classified 52.1% as very low, 26.6% low, 17.5% middle, 2.8% high, and 1% as very high risk, while the Fuchs score identified 94.5% as low-risk and 5.5% as high-risk patients. Mortality rates were 6.9% at 90 days, 3.4% at 30 days, and 6.7% in-hospital. The area under the ROC curve was 0.634 (95%CI: 0.557-0.712) for the IESG model, 0.637 (95%CI: 0.526-0.747) for the Steyerberg score, and 0.686 (95%CI: 0.611-0.760) for the Fuchs score.</p><p><strong>Conclusions: </strong>Existing risk score systems provide a possibility for preoperative risk stratification, particularly for identifying high-risk patients. However, due to their limited predictive ability, improvements are needed to apply these strategies effectively in clinical practice.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"51"},"PeriodicalIF":2.7,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11775027/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Practitioners' perspective: a mixed-methods study on dealing with suicidality from the perspective of oncological healthcare professionals.","authors":"Tamara Schwinn, Judith Hirschmiller, Jörg Wiltink, Rüdiger Zwerenz, Elmar Brähler, Manfred E Beutel, Mareike Ernst","doi":"10.1007/s00432-025-06106-z","DOIUrl":"10.1007/s00432-025-06106-z","url":null,"abstract":"<p><strong>Purpose: </strong>Healthcare professionals (HCPs) play a critical role in suicide prevention and clinical guidelines recommend inquiring about suicidality as part of medical history and diagnosis. Emerging evidence indicates a lack of implementation of such policies in clinical practice. However, to date, no comprehensive mixed-methods study has examined this issue in the field of oncology.</p><p><strong>Methods: </strong>A preregistered mixed-methods study was conducted with oncological HCPs (N = 20) from various professions, using semi-structured interviews and validated questionnaires. Employing an explorative theory-generating approach, qualitative content analysis was applied to the interviews. The different data sources are integrated and contrasted. Comparisons according to sociodemographic variables (profession, age, and gender) and frequency distributions were used to examine the questionnaire data.</p><p><strong>Results: </strong>Most HCPs reported direct or indirect experiences with suicidality in cancer patients. Nineteen HCPs did not routinely explore suicidality, of whom five reported not inquiring about it at all. Those who explored suicidality were more confident, less emotionally overwhelmed and reported higher subjective knowledge. HCPs also differed regarding their endorsement of suicide myths.</p><p><strong>Conclusion: </strong>The study highlights difficulties with active suicide exploration and differences among HCPs. Integrating these findings into education and training could improve HCPs' skills and reduce disparities, supporting successful suicide prevention.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"54"},"PeriodicalIF":2.7,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11775075/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}